

# **EPIPERICARDIAL FAT NECROSIS AND COVID-19**

Mohsin Haseeb<sup>1</sup>, Abdullah Shafiq<sup>2</sup>, Muhammad A. Sheikh<sup>2</sup>, Muhammad F. Khan<sup>2</sup>

<sup>1</sup> Department of Cardiology, University of Illinois College of Medicine, Peoria, USA

<sup>2</sup> Department of Cardiology, Southern Illinois University, Illinois, USA

Corresponding author: Mohsin Haseeb e-mail: mohsinhaseeb157@gmail.com

Received: 31/01/2024 Accepted: 05/02/2024 Published: 29/02/2024

Conflicts of Interests: The Authors declare that there are no competing interests. Patient Consent: We obtained informed consent for this publication from the patient. This article is licensed under a Commons Attribution Non-Commercial 4.0 License

How to cite this article: Haseeb M, Shafiq A, Sheikh MA, Khan MF. Epipericardial fat necrosis and COVID-19. EJCRIM 2024;11:doi:10.12890/2024\_004346.

## ABSTRACT

*Background*: Epipericardial fat necrosis (EFN) is a rare and self-limiting cause of acute chest pain. We describe a case of EFN in a patient with a recent coronavirus disease (COVID-19).

*Case Presentation*: A 55-year-old male presented with a sudden onset of left-sided pleuritic chest pain for the past two days. The patient was diaphoretic, tachypneic, and tachycardic. Acute coronary syndrome was ruled out. A computed tomography (CT) pulmonary angiogram revealed an ovoid encapsulated fatty mass surrounded by dense appearing tissue. Patient symptoms improved remarkably with a short course of non-steroidal anti-inflammatory drugs (NSAIDs).

*Discussion*: EFN typically presents with a sudden onset of excruciating chest pain. Misdiagnosis, under-diagnosis, and mismanagement are unavoidable. EFN is incidentally diagnosed on CT scan. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects visceral adipose tissue and appears to increase the risk of EFN by promoting inflammatory cytokine production and death of adipocytes.

*Conclusion*: EFN is a rare cause of acute chest pain. SARS-CoV-2 is likely to induce EFN. This rare clinical entity should be considered in the differential of acute chest pain especially in patients with active or recent COVID-19.

## **KEYWORDS**

Epipericardial fat necrosis, chest pain, COVID-19, epipericardial adipose tissue

## **LEARNING POINTS**

- Epipericardial fat necrosis (EFN) is a rare cause of acute pleuritic chest pain that is often misdiagnosed and mismanaged.
- SARS-CoV-2 can possibly increase the risk of EFN and this entity should be considered in the differential of chest pain, especially in patients with active or recent coronavirus disease (COVID-19).
- Clinician awareness of EFN and its potential association with COVID-19, can reduce unnecessary testing and emotional distress.

## **INTRODUCTION**

Epipericardial fat necrosis (EFN) is a rare and self-limiting cause of acute chest pain that mimics serious clinical

conditions such as acute coronary syndrome (ACS) and pulmonary embolism (PE). We describe a case of EFN in a patient with a recent coronavirus disease (COVID-19).





#### **CASE DESCRIPTION**

A 55-year-old male with a past medical history of hypertension and hyperlipidaemia presented with sudden onset of excruciating left-sided pleuritic chest pain and shortness of breath for the past two days. The patient was diagnosed with COVID-19 two weeks prior. Physical examination revealed diaphoresis, tachypnoea, tachycardia and reduced breath sounds at the base of the lung. The white blood cell (WBC) count and C-reactive protein (CRP) level were mildly elevated. Multiple electrocardiograms and serum biomarkers for myocardial ischemia and venous thromboembolism were unremarkable. A chest X-ray showed bilateral basilar opacities. Because of the persistent chest pain, a computed tomography (CT) pulmonary angiogram revealed findings suggestive of EFN (Fig. 1). The patient was treated with ibuprofen and his symptoms resolved in two weeks.

#### DISCUSSION

EFN is a rare and self-limiting cause of acute chest pain. The prevalence, based on limited studies, is approximately 2% in patients presenting to the Emergency Department with atypical chest pain<sup>[1]</sup>. However, only 57 cases of EFN have been reported in the English-language medical literature from 1957 to 2016; highlighting the problem of underdiagnosis<sup>[1]</sup>. In addition, misdiagnosis, and mismanagement are unavoidable and lead to excessive diagnostic work up and emotional distress for the patient<sup>[1,2]</sup>. The definitive cause of EFN is unclear but different mechanisms have been proposed: haemorrhagic necrosis induced by a sudden increase in intrathoracic pressure due to the Valsalva manoeuvre, ischemia secondary to torsion of a vascularized pedicle, and pre-existing benign tumours of epicardial adipose tissue such as lipoma and hamartoma. Updated evidence has ruled out obesity as a risk factor<sup>[1]</sup>. The patient typically presents with sudden onset of excruciating chest pain which increases with inspiration and is predominantly left-sided<sup>[1]</sup>. During the earlier stage of the disease, the patient may be in severe distress and may have tachypnoea, tachycardia, or diaphoresis -mimicking life-threatening clinical conditions such as pneumothorax, ACS, and, PE<sup>[2]</sup>. Laboratory tests may reveal a mildly elevated WBC count and inflammatory biomarkers. Cases of EFN are usually detected incidentally on CT scan, and CT scan is the imaging modality of choice for the diagnosis of EFN<sup>[1,2]</sup>. Characteristic radiologic findings are an ovoid encapsulated fatty mass encased by varying degrees of inflammatory stranding of the surrounding tissue<sup>[1]</sup>. A triad of pleuritic chest pain, typical radiologic findings, and focal pericardial thickening is highly suggestive of EFN<sup>[1]</sup>. In the majority of cases, a short course of nonsteroidal anti-inflammatory agents provides excellent symptom relief<sup>[1]</sup>. With the current widespread use of advanced imaging modalities; thoracotomy, once preformed frequently, has fallen out of favour. Follow-up imaging is typically done to rule out underlying benign tumours such as lipoma and hamartoma<sup>[1,2]</sup>.




Figure 1. Computed tomography scan of the chest demonstrating epipericardial fat necrosis (yellow arrow) as an oval-shaped mass, with a central hypodense area, surrounded by a rim of hyperdense, inflammatory tissue.

In the literature, there is very little evidence of recent or concomitant infection in patients with EFN<sup>[2]</sup>. We have described a rare case of EFN in a patient with a recent COVID-19. We also highlight two recently reported cases of EFN in patients with recent SARS-CoV-2 infection suggesting the possibility that SARS-CoV-2 is likely to induce EFN<sup>[3,4]</sup>. To explain this possible association, we identified a close link between SARS-CoV-2 and visceral fat<sup>[5]</sup>. Visceral adipocytes are more prone to SARS-CoV-2 infection than subcutaneous adipocytes because of increased expression of ACE2 receptors<sup>[5]</sup>. Adipocytes, in vitro, infected by SARS-CoV-2 demonstrate upregulated inflammatory cytokine expression and increased cell death<sup>[5]</sup>. Epicardial adipose tissue also promotes the development of coronary artery disease, heart failure, and atrial fibrillation possibly via inflammatory cytokines<sup>[6]</sup>. Beside visceral tissue, SARS-CoV-2 also increases inflammatory cytokine levels in plasma<sup>[7]</sup>. Epicardial adipose tissue is postulated to be a reservoir and amplifier of COVID-19<sup>[8]</sup>. Inflammation of epicardial adipose tissue increases with severity of COVID-19 and decreases with the use of steroids suggesting a close link between visceral adipose tissue and SARS-CoV-2<sup>[6]</sup>.

#### CONCLUSION

We conclude that SARS-CoV-2 appears to increase the risk of EFN and this rare clinical entity should be considered in the differential of acute chest pain, especially in patients with concomitant or recent COVID-19. Clinician awareness of this uncommon disease and its association with COVID-19 can prevent unnecessary testing, mismanagement, and emotional distress in patients.

#### REFERENCES

- Mortensen SG, Buchmann P, Lappegård KT. Epipericardial Fat Necrosis: A Case Report and a Review of the Literature. *Clin Med Insights Case Rep* 2020;13:1179547620940769.
- Fred HL. Pericardial fat necrosis: a review and update. Tex Heart Inst J 2010;37:82-84.
- You J, Hou L, Chatterjee S, Bhansali RD. Epipericardial fat necrosis: a rare, potential complication of COVID-19 pneumonia. J Am Coll Cardiol 2022;79:2370.
- 4. Zayour M, Karari M, Al Ashkar R, Chammas E. Epicardial Fat Necrosis After COVID-19 Infection: A Case Report. *Cureus* 2022;**14**:e25154.
- Saccon TD, Mousovich-Neto F, Ludwig RG, Carregari VC, dos Anjos Souza AB, dos Passos ASC, et al. SARS-CoV-2 infects adipose tissue in a fat depot- and viral lineage-dependent manner. *Nat Commun* 2022;13:5722.
- Iacobellis G. Epicardial adipose tissue in contemporary cardiology. Nat Rev Cardiol 2022;19:593-606.
- 7. Tajbakhsh A, Gheibi Hayat SM, Taghizadeh H, Akbari A, Inabadi M, Savardashtaki A, et al. COVID-19 and cardiac injury: clinical manifestations, biomarkers, mechanisms, diagnosis, treatment, and follow up. *Expert Rev Anti Infect Ther* 2021;**19**:345-357.
- Malavazos AE, Goldberger JJ, Iacobellis G. Does epicardial fat contribute to COVID-19 myocardial inflammation? *Eur Heart J* 2020;41:2333.